Literature DB >> 19332250

Management of early and locally advanced cervical cancer.

Lisa Barbera1, Gillian Thomas.   

Abstract

Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early and locally advanced cervical carcinoma is reviewed, including staging, imaging, prognostic factors, and primary and adjuvant therapy and their outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19332250     DOI: 10.1053/j.seminoncol.2008.12.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  16 in total

1.  Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature.

Authors:  Seiji Mabuchi; Kenichirou Morishige; Takayuki Enomoto; Tadashi Kimura
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

2.  The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI.

Authors:  Christine Ellingsen; Stefan Walenta; Tord Hompland; Wolfgang Mueller-Klieser; Einar K Rofstad
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

3.  High expression of CRAM correlates with poor prognosis in patients with cervical carcinoma.

Authors:  Teng Hou; Dongxia Liang; Dong Yang; Jiehua He; Yongwen Huang; Yanna Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

4.  Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer.

Authors:  Ken Yoshida; Hideya Yamazaki; Satoaki Nakamura; Koji Masui; Tadayuki Kotsuma; Hironori Akiyama; Eiichi Tanaka; Nobuhiko Yoshikawa; Yasuo Uesugi; Taiju Shimbo; Yoshifumi Narumi; Yasuo Yoshioka
Journal:  J Gynecol Oncol       Date:  2015-04-29       Impact factor: 4.401

Review 5.  STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy.

Authors:  Melanie Spitzner; Reinhard Ebner; Hendrik A Wolff; B Michael Ghadimi; Jürgen Wienands; Marian Grade
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

6.  Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

Authors:  Ming-Mo Hou; Xiaochun Liu; Jennifer Wheler; Aung Naing; David Hong; Robert L Coleman; Apostolia Tsimberidou; Filip Janku; Ralph Zinner; Karen Lu; Razelle Kurzrock; Siqing Fu
Journal:  Oncotarget       Date:  2014-11-30

7.  Survivin Overexpression Is Associated with Aggressive Clinicopathological Features in Cervical Carcinoma: A Meta-Analysis.

Authors:  Ke-Yan Cheng; Zhi-Lian Wang; Qian-Yun Gu; Min Hao
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

8.  Cohort Profile: Chinese Cervical Cancer Clinical Study.

Authors:  Xi-Ru Zhang; Zhi-Qiang Li; Li-Xin Sun; Ping Liu; Zhi-Hao Li; Peng-Fei Li; Hong-Wei Zhao; Bi-Liang Chen; Mei Ji; Li Wang; Shan Kang; Jing-He Lang; Chen Mao; Chun-Lin Chen
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

9.  Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.

Authors:  Christine Ellingsen; Lise Mari K Andersen; Kanthi Galappathi; Einar K Rofstad
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

10.  Prevalence of Specific Types of Human Papiloma Virus in Cervical Intraepithelial Lesions and Cervical Cancer in Macedonian Women.

Authors:  Irena Aleksioska-Papestiev; Vesna Chibisheva; Megi Micevska; Goran Dimitrov
Journal:  Med Arch       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.